What the FDA labels say about taking them together
Aliskiren and telmisartan
Telmisartan's FDA label of May 29, 2026 names aliskiren in its contraindications section; aliskiren's label does not name telmisartan itself but warns about its class (ARBs (angiotensin II receptor blockers)). The telmisartan label: “Do not co-administer aliskiren with telmisartan in patients with diabetes.”
Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the telmisartan FDA label on DailyMed (effective May 29, 2026, Alembic Pharmaceuticals Limited).
What does the aliskiren label say about telmisartan?
Aliskiren's label does not name telmisartan itself; it warns about its class (ARBs (angiotensin II receptor blockers)):
Aliskiren label, warnings and precautionsRenal Impairment/Hyperkalemia/Hypotension when Tekturna is Given in Combination with ARBs or ACEIs Tekturna is contraindicated in patients with diabetes who are receiving ARBs or ACEIs because of the increased risk of renal impairment, hyperkalemia, and hypotension.
Aliskiren label, contraindicationsCONTRAINDICATIONS Do not use Tekturna with ARBs or ACEIs in patients with diabetes [see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.3 )].
Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed
What does the telmisartan label say about aliskiren?
Telmisartan label, contraindicationsDo not co-administer aliskiren with telmisartan in patients with diabetes [see Drug Interactions (7)].
Telmisartan label, drug interactionsAvoid use of aliskiren with telmisartan in patients with renal impairment (GFR <60 ml/min).
Telmisartan label, warnings and precautionsBlockade of the Renin-Angiotensin-Aldosterone System (RAS) Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Source: FDA drug label (Telmisartan), Alembic Pharmaceuticals Limited, effective May 29, 2026 (SPL set 4be6575f-ea8d-4cd8-a49d-3d1c93f2621a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aliskiren | Telmisartan | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure, Heart attack and coronary artery disease |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $3.94 per tablet 150 mg tablet | $0.106 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once